Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis

Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis

The aim of this study was to assess abatacept in rheumatoid arthritis (RA) patient. Patients (20 men, 89 women, aged 61.9 ± 10.4 y) who responded inadequately to conventional synthetic disease-modifying anti-rheumatic drug were treated with abatacept for 24-months. Disease activity score in 28 joint...

Full description

Bibliographic Details
Main Authors:	Noriyoshi Ogawa, Hiroyuki Ohashi, Yasuhiro Ota, Kaori Kobori, Motohiro Suzuki, Seiji Tsuboi, Masakatsu Hayakawa, Yoshinori Goto, Taro Karahashi, Osamu Kimoto, Toshiaki Miyamoto, Shogo Furukawa, Kumiko Shimoyama, Daisuke Suzuki, Yuichiro Maekawa
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2019-01-01
Series:	Immunological Medicine
Subjects:	rheumatoid arthritis abatacept cytokines anti-citrullinated peptide antibody
Online Access:	http://dx.doi.org/10.1080/25785826.2019.1605036

Similar Items

Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production
by: Hisakata Yamada, et al.
Published: (2020-04-01)

The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study
by: Paul Emery, et al.
Published: (2023-04-01)

ABATACEPT FOR RHEUMATOID ARTHRITIS: A NOVEL FORMULATION, NEW MECHANISMS, NEW POSSIBILITIES
by: E. L. Nasonov
Published: (2015-10-01)

Abatacept downregulates Fcγ receptor I on circulating monocytes: a potential therapeutic mechanism in patients with rheumatoid arthritis
by: Ryosuke Fukue, et al.
Published: (2022-08-01)

Benefits of Autoantibody Enrichment in Early Rheumatoid Arthritis: Analysis of Efficacy Outcomes in Four Pooled Abatacept Trials
by: Kaleb Michaud, et al.
Published: (2023-05-01)

HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA
by: William Rigby, et al.
Published: (2021-09-01)

Desarrollo de psoriasis durante el tratamiento con Abatacept en artritis reumatoidea
by: J.A. Riera, et al.
Published: (2019-06-01)

Uso do abatacepte em uma paciente com artrite psoriásica Use of the abatacept in a patient with psoriatic arthritis
by: Carlos Ewerton Maia Rodrigues, et al.
Published: (2010-06-01)

Use of abatacept in rheumatoid arthritis
by: Johannes von Kempis, et al.
Published: (2012-05-01)

EXPERIENCE WITH ABATACEPT IN TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS
by: Margarita Fedorovna Dubko, et al.
Published: (2012-10-01)

Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network
by: Jean-Hugues Salmon, et al.
Published: (2020-05-01)

Pre-silencing of genes involved in the electron transport chain (ETC) pathway is associated with responsiveness to abatacept in rheumatoid arthritis
by: C. Derambure, et al.
Published: (2017-05-01)

Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis
by: Paul Emery, et al.
Published: (2023-03-01)

Abatacept induced granulomatous hepatitis with a sarcoidosis- like reaction: a blinded trial in mice
by: Sultan M. Almogairen
Published: (2019-05-01)

Re-administration of abatacept for the control of articular symptoms of rheumatoid arthritis during anti-tuberculous therapy
by: Hironori Kawamoto, M.D., et al.
Published: (2017-01-01)

Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis
by: Suzuki T, et al.
Published: (2018-03-01)

Experience with abatacept used in the treatment of patients with rheumatoid arthritis
by: V I Mazurov, et al.
Published: (2011-12-01)

EXPERIENCE OF TREATMENT WITH ABATACEPT IN PATIENTS WITH JUVENILE RHEUMATOID ARTHRITIS
by: Ye. I. Alekseyeva, et al.
Published: (2011-01-01)

Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis
by: Shuzo Sato, et al.
Published: (2021-08-01)

Tocilizumab and Abatacept for the Treatment of Childhood Chronic Uveitis: A Monocentric Comparison Experience
by: Ilaria Maccora, et al.
Published: (2022-04-01)

Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis
by: Waka Yokoyama-Kokuryo, et al.
Published: (2020-03-01)

Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates
by: Laetitia Diep, et al.
Published: (2022-10-01)

Current treatment options for psoriatic arthritis: spotlight on abatacept
by: Ursini F, et al.
Published: (2018-06-01)

Rituximab and Abatacept Are Effective in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies
by: Yulia Rodina, et al.
Published: (2021-09-01)

Abatacept is effective in Chinese patients with LRBA and CTLA4 deficiency
by: Lu Yang, et al.
Published: (2021-09-01)

Efficacy and tolerability of abatacept treatment: results of 12 months observation
by: M A Borisova, et al.
Published: (2018-05-01)

COMPARATIVE EVALUATION OF THE EFFICACY AND SAFETY OF ABATACEPT IN PATIENTS WITH DIFFERENT DURATION OF RHEUMATOID ARTHRITIS
by: M. A. Borisova, et al.
Published: (2017-01-01)

Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis–Associated Interstitial Lung Disease
by: Natalia Mena-Vázquez, et al.
Published: (2022-06-01)

Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis
by: Agnes Szentpetery, et al.
Published: (2017-07-01)

Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive
by: Leslie R. Harrold, et al.
Published: (2024-01-01)

Monocyte-derived transcriptomes explain the ineffectiveness of abatacept in rheumatoid arthritis
by: Takeshi Iwasaki, et al.
Published: (2024-01-01)

Immunomodulatory mechanisms of abatacept: A therapeutic strategy for COVID-19
by: Dinglong Yang, et al.
Published: (2022-07-01)

Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data
by: Teresa A. Simon, et al.
Published: (2021-01-01)

Risk of hepatitis B virus reactivation following treatment with abatacept: A retrospective study of international pharmacovigilance databases
by: Jingjing Wang, et al.
Published: (2022-06-01)

Abatacept increases T cell exhaustion in early RA individuals who carry HLA risk alleles
by: Sarah Alice Long, et al.
Published: (2024-04-01)

Abatacept as salvage therapy for life-threatening refractory autoimmune hemolytic anemia: a case report
by: Joerg Hoffmann, et al.
Published: (2023-12-01)

Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study
by: Ernest Choy, et al.
Published: (2021-02-01)

Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy
by: Roberto Caporali, et al.
Published: (2021-07-01)

Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abatacept
by: Louis Bessette, et al.
Published: (2023-09-01)

Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis
by: Wataru Hirose, et al.
Published: (2021-08-01)